Literature DB >> 9039704

Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes.

M Maarouf1, F Lawrence, S Brown, M Robert-Gero.   

Abstract

Paromomycin is used for the treatment of leishmaniasis in humans, but little is known about its mechanism of action. Investigating the effect of this antibiotic on promastigotes of Leishmania donovani, we showed that inhibition of the multiplication of these parasites could be related to its effect on RNA synthesis and to modifications of membranous polar lipids and membrane fluidity, leading to altered membrane permeability.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9039704     DOI： 10.1007/s004360050232

Source DB:  PubMed          Journal:  Parasitol Res        ISSN： 0932-0113            Impact factor:   2.289


  15 in total

1.  Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.

Authors:  Marta Gontijo Aguiar; Aline Márcia Machado Pereira; Ana Paula Fernandes; Lucas Antonio Miranda Ferreira
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

2.  Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.

Authors:  Prachi Bhalla; Sabera Sultana; Adarsh Kumar Chiranjivi; Anil K Saikia; Vikash Kumar Dubey
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.

Authors:  Nishi Shakya; Preeti Bajpai; Suman Gupta
Journal:  J Parasit Dis       Date:  2011-05-20

4.  Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation.

Authors:  Antara Banerjee; Manjarika De; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

5.  Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.

Authors:  Arpita Kulshrestha; Ruchi Singh; Dhiraj Kumar; Narender Singh Negi; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

6.  Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells.

Authors:  Marisa M Fernández; Emilio L Malchiodi; Israel D Algranati
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

7.  Mechanism of amphotericin B resistance in Leishmania donovani promastigotes.

Authors:  N Mbongo; P M Loiseau; M A Billion; M Robert-Gero
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

8.  Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.

Authors:  Vasundhra Bhandari; Shyam Sundar; Jean Claude Dujardin; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

9.  Paromomycin: uptake and resistance in Leishmania donovani.

Authors:  Anupam Jhingran; Bhavna Chawla; Shailendra Saxena; Michael Peter Barrett; Rentala Madhubala
Journal:  Mol Biochem Parasitol       Date:  2008-12-25       Impact factor: 1.759

10.  Insights of antiparasitic activity of sodium diethyldithiocarbamate against different strains of Trypanosoma cruzi.

Authors:  Johny Wysllas de Freitas Oliveira; Taffarel Melo Torres; Cláudia Jassica Gonçalves Moreno; Bruno Amorim-Carmo; Igor Zumba Damasceno; Ana Katarina Menezes Cruz Soares; Jefferson da Silva Barbosa; Hugo Alexandre Oliveira Rocha; Marcelo Sousa Silva
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.